摘要
目的 考察卡维地洛对轻、中度原发性高血压患者血脂的影响。方法 经多中心临床试验 ,随机双盲试验组 10 0对 ,与拉贝洛尔 (Labetalol)作平行对照 ,开放试验 30 0例 ,自身前后对照。结果 组内配对t检验表明 ,卡维地洛和拉贝洛尔两组给药前后TCH、TG、HDL均无显著差异。组间比较也无显著差异 ;开放试验表明 ,卡维地洛给药前后TCH、TG的变化无显著差异。结论 卡维地洛为兼有α1 受体阻断作用的 β 受体阻断剂 ,无内在拟交感活性 ,对脂质代谢没有不良影响 ,因而具有较大的优越性 。
Aim To investigate the effect of carvedilol on serum lipids in patients with mild-to-moderate essential hypertension.Methods A multicenter clinic trial was carried out in patients with stage I～II essential hypertension.One hundred pairs patients were enrolled in random,double blind trial with labetalol as control,while 300 patients were in open trial.Results After 4 weeks treatment, in random, double blind trial,serum lipids [total cholesterol(TCH), triglycerides(TG), high-density lipoprotein (HDL)] were not altered significantly in both carvedilol and labetalol administration. In open trial,TCH,TG were not altered significantly,too.Conclusion From these results,it can be concluded that carvedilol has no adverse effects on the coronary risk profile as reflected by lipid measurements, and is an efficacious, safe, well-tolerated antihypertensive drug in patients with mild-to-moderate hypertension.
出处
《解放军药学学报》
CAS
2001年第1期28-29,共2页
Pharmaceutical Journal of Chinese People's Liberation Army
